Telomir Pharmaceuticals, Inc.
TELO Nasdaq
SEC CIK 1971532
Follow Telomir Pharmaceuticals
Weekly email: filings, results
Net income
−$705.2K
+36% vs same quarter last year
EPS, diluted
−$0.01
+66.7% vs same quarter last year
Operating cash flow
−$586.4K
+36.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$10.4M |
| FY24 | −$16.5M |
| FY23 | - |
| FY22 | −$854.1K |
| FY21 | - |